Life Sciences

  • July 29, 2026

    Albertsons Pharmacy Work Was 'House Of Cards,' Judge Told

    Albertsons pharmacists in Washington state repeatedly warned supervisors that busy workloads and limited staffing were making it difficult to review prescriptions before filling them, a state judge in Seattle heard Monday, during a bench trial in Washington's case accusing Albertsons and its Safeway subsidiary of fueling the state's opioid crisis.

  • July 29, 2026

    2nd Circ. Backs Ex-Shkreli Atty's 401(k) Restitution Deal

    A New York trial judge erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from tax penalties, the Second Circuit ruled Wednesday.

  • July 29, 2026

    Novo Faces Narrowed Investor Suit Over Obesity Drug Claims

    A New Jersey federal judge narrowed a proposed securities class action against Novo Nordisk, preserving claims that it misled investors about the CagriSema obesity drug's tolerability and a flexible protocol used in a clinical trial.

  • July 29, 2026

    Depo-Provera MDL Gets New Lead Plaintiffs After Settlement

    The Florida federal judge overseeing the multidistrict litigation over a link between brain tumors and the hormonal contraceptive Depo-Provera on Wednesday approved three new pilot plaintiffs for the cases remaining after a global settlement that the judge called an "excellent outcome."

  • July 29, 2026

    Curaleaf Says Pot Suit Is Long On Length But Not Substance

    Cannabis giant Curaleaf Holdings Inc. on Tuesday slammed as "ill-conceived" a proposed class action by consumers who claim the company falsely marketed its products as medical treatments for mental health disorders and physical pain, saying none of the buyers are even medical cannabis patients.

  • July 29, 2026

    FTC Says Hims & Hers Shares Health Data, Misleads Users

    The Federal Trade Commission and regulators in California and Utah allege in a federal lawsuit filed Wednesday that Hims & Hers promises patient privacy while actually sharing consumers' sensitive health information with Meta Platforms and other third-party advertising platforms and that the telehealth provider has deceived users about its billing practices.

  • July 29, 2026

    Colo. Hospital Patients In Gender Care Suit Seek Class Cert.

    Transgender adolescents urged a Colorado state judge Wednesday to allow them to proceed as a certified class in their lawsuit seeking to have Children's Hospital Colorado resume providing gender-affirming care for them and other transgender youth patients, arguing the class is "objectively definable."

  • July 29, 2026

    9th Circ. Revives Biotech Worker's Pension Plan Suit

    The Ninth Circuit reopened a former Calbiotech Inc. scientist's lawsuit claiming the company unlawfully hid the existence of a pension plan, saying a trial court erred in concluding that a document specifying who was eligible to participate in the plan was legitimate.

  • July 29, 2026

    Planned Parenthood Lab's $6.1M Breach Deal Gets Initial OK

    A Washington federal judge has preliminarily approved a $6.1 million class action settlement in two challenges to a state-based diagnostics testing service for Planned Parenthood over a 2025 data breach that reportedly affected as many as 1.6 million people.

  • July 29, 2026

    Health Economist's Report Cleared For Generic-Drug MDL

    The Pennsylvania federal judge overseeing the multidistrict litigation over generic-drug price-fixing claims has ruled that Humana's health economist's expert report can be admitted into evidence, rejecting several pharmaceutical companies' argument that his findings were based on a flawed methodology.

  • July 29, 2026

    J&J Says Cancer Drug Study Sinks Bayer's False Ad Claims

    Johnson & Johnson told a New York federal court that a peer-reviewed scientific journal's publication of a study on the active ingredient in its prostate cancer drug must end Bayer's claims the pharmaceutical giant made false and misleading claims about the drug's efficacy.

  • July 29, 2026

    Attys Secure $15M Fees In Abbott Formula Shareholder Suit

    An Illinois federal judge on Wednesday approved class counsel's $15.3 million fee request in a shareholder dispute over Abbott Laboratories' management of a 2022 infant formula contamination crisis, satisfied with the elaboration he called for during an earlier settlement fairness hearing.

  • July 28, 2026

    No COVID Immunity For Mich. Hospitals In Malpractice Revival

    Just because a motion is unopposed doesn't mean it should be granted, Michigan appellate judges said in a published opinion Tuesday, reversing a trial court's decision that the Pandemic Health Care Immunity Act shielded Beaumont Hospital Farmington Hills from a medical malpractice suit.

  • July 28, 2026

    NC Woman Drops Bone Cement Suit Against Zimmer Biomet

    A woman agreed to permanently end her lawsuit against medical device manufacturer Zimmer Biomet, in which she claimed its compound for bonding prosthetics to bone was defective and caused her to suffer following a knee replacement surgery.

  • July 28, 2026

    340B Appellate Cases To Watch In The 2nd Half Of 2026

    Drugmakers are pressing appellate judges in the back half of 2026 to strike down state laws blocking them from restricting 340B contract pharmacy arrangements. Law360 Healthcare Authority has the cases to watch.

  • July 28, 2026

    Teva Can't 'Literally Whine' Of Being Held To DOJ Admissions

    A Pennsylvania federal judge has taken Teva to task for trying to avoid being held to its admissions of price-fixing in a $225 million settlement with the U.S. Department of Justice, ruling that Humana can use those admissions in one of the first bellwether trials in sprawling multidistrict litigation.

  • July 28, 2026

    Goodwin Grows Life Sciences Group With San Diego IP Hire

    Goodwin Procter LLP announced Monday that an experienced intellectual property attorney focused on life sciences matters has joined the firm's San Diego office as a partner from Wilson Sonsini Goodrich & Rosati PC.

  • July 28, 2026

    Trader In BigLaw Deal-Tipping Scheme To Plead Guilty

    A Florida resident is set to plead guilty to his alleged role in a sweeping scheme to trade on insider information about impending acquisitions that was stolen from major law firms, according to a court filing Tuesday.

  • July 27, 2026

    Albertsons Opioid Trial Told Of Needles, ODs In Library

    A witness in Washington's case accusing Albertsons Cos. Inc. of fueling the state's opioid crisis testified at a bench trial Monday that problem drug use was evident in a city library system she's led for nearly a decade, pointing to syringes scattered across the facility and multiple instances of overdoses.

  • July 27, 2026

    J&J, Ovarian Cancer Talc Claimants Unveil $5.5B Global Deal

    Johnson & Johnson announced Monday that it has agreed to pay some $5.5 billion to put to rest tens of thousands of lawsuits alleging its talcum powder products caused ovarian cancer, with plaintiffs' counsel calling the deal "long-delayed justice" for their clients.

  • July 27, 2026

    Union Funds Seek Final OK For $180M In Opioid Deals

    Union health and welfare funds have asked the Ohio federal judge overseeing the sprawling national opioid litigation to approve settlements totaling $180 million with CVS, Walgreens, Walmart and three pharmaceutical companies to compensate for the costs of opioid use disorder treatment.

  • July 27, 2026

    Taco Bell, Taylor Farms Hit With Another Cyclospora Suit

    Consumers have filed another suit in Michigan federal court against Taco Bell and produce supplier Taylor Farms, alleging that the companies' negligence caused them to suffer cyclospora infections after eating contaminated iceberg lettuce sold at Taco Bell restaurants.

  • July 27, 2026

    Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case

    The Federal Circuit on Monday overturned a $49.4 million patent judgment against Boston Scientific, ruling that the company's drug-eluting coronary stents did not infringe a patent owned by the University of Texas System and that the patent is invalid.

  • July 27, 2026

    Hygiene Co. Can't Fight FTC's Need To Back Up COVID Claims

    Xylitol-based hygiene products company Xlear can't challenge the Federal Trade Commission's general insistence that companies "substantiate" health claims like COVID-19 protections, because the FTC isn't currently suing over those claims, a Utah federal judge ruled Monday.

  • July 27, 2026

    Cooley Owes $25.4M Judgment To NJ Biotech Co. Founder

    A New Jersey state court on Monday entered a $25.4 million judgment against Cooley LLP after a jury found the multinational firm had committed malpractice in its representation of a biotech founder who said his own lawyers assisted in shoving him out of his company.

Expert Analysis

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.